← Back to patent-cliff list

BNC-105P

Tier C — Watch / trade

BNC-105P

Bionomics Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:Tubulin

Indications (approved):Colorectal cancer, Ovarian cancer, Renal cell carcinoma

Regional status

US
Discontinued
2010-01-01
EU
-
China
-
Japan
-

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 8 · Total yield 62 mg
BNC-105-001905751-80-6BNC-105-002154673-66-2BNC-105-0031269439-44-2BNC-105-004905752-32-1BNC-105-00525245-29-8BNC-105-006905752-33-2BNC-105-007905752-39-8BNC-105-008905752-30-9BNC-105-009945771-74-4BNC-105-01017176-77-1BNC-105-011945828-45-5API · BNC-105P
CodeCAS No.Intermediate
BNC-105-001905751-80-66-iodo-2-isopropoxy-3-methoxyphenol
BNC-105-002154673-66-2tert-butyl(3-((tert-butyldimethylsilyl)oxy)prop-1-yn-1-yl)dimethylsilane
BNC-105-0031269439-44-2(E)-tert-butyl((2-(tert-butyldimethylsilyl)-7-isopropoxy-6-methoxybenzofuran-3(2H)-ylidene)methoxy)dimethylsilane
BNC-105-004905752-32-12-(tert-butyldimethylsilyl)-7-isopropoxy-6-methoxybenzofuran-3-carbaldehyde
BNC-105-00525245-29-85-iodo-1,2,3-trimethoxybenzene
BNC-105-006905752-33-2(2-(tert-butyldimethylsilyl)-7-isopropoxy-6-methoxybenzofuran-3-yl)(3,4,5-trimethoxyphenyl)methanone
BNC-105-007905752-39-82-(tert-butyldimethylsilyl)-6-methoxy-3-(3,4,5-trimethoxybenzoyl)benzofuran-7-yl acetate
BNC-105-008905752-30-92-bromo-6-methoxy-3-(3,4,5-trimethoxybenzoyl)benzofuran-7-yl acetate
BNC-105-009945771-74-4(7-hydroxy-6-methoxy-2-methylbenzofuran-3-yl)(3,4,5-trimethoxyphenyl)methanone
BNC-105-01017176-77-1dibenzyl phosphonate
BNC-105-011945828-45-5dibenzyl (6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzofuran-7-yl) phosphate

Frequently asked questions

What are the approved indications of BNC-105P?

Approved indications include: Colorectal cancer, Ovarian cancer, Renal cell carcinoma.

When does the BNC-105P patent expire?

No public expiry year is available for BNC-105P yet; this page updates once verified.

How many synthesis routes are recorded for BNC-105P?

1 synthesis routes are recorded; the shortest is 8 steps with 62 mg total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy BNC-105P intermediates?

All intermediates in BNC-105P routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.

How do I get a quote for BNC-105P intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-21